This editorial refers to 'Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX 3 CL1/CX 3 CR1 axis' by S. , this issue.
The mechanisms driving accelerated atherosclerosis in insulin-resistant (IR) conditions, such as Type 2 diabetes and the metabolic syndrome, are incompletely understood. Clarifying such pathways is of paramount importance in view of the epidemic spread of obesity and diabetes, and in order to devise novel therapeutic approaches to counter cardiovascular disease globally. IR develops classically in metabolically active tissues (such as the liver, muscle, and fat), but the vasculature can also show signs of IR, 1 with impairment in the Erk and Akt pathways.
Many cell types are involved in the atherogenetic process and complex cross-talks take place within the atherosclerotic plaque. Vascular smooth muscle cells (VSMCs) and monocyte-macrophage lineage cells are two major players provided with both protective and pathogenic functions. VSMC proliferation promotes plaque growth, but also forms the fibrous cap of the atheroma, a thick and resistant shield against plaque rupture and thrombosis. However, VSMCs from human atherosclerotic vessels are senescent and intrinsically prone to apoptosis. 2, 3 In fact, when
VSMCs undergo apoptosis, atherosclerosis accelerates, and plaques become unstable 4,5 and calcific. 6 Vice versa, inhibition of apoptosis blunts the atherosclerotic process. 7 This finely tuned balance between VSMC proliferation and death is a key determinant of atheroma progression. 8 Monocyte-macrophage cells can exist in two distinct states with opposing effects on atherosclerosis. 9 According to the pattern of local stimuli, macrophages can be polarized towards a pro-inflammatory (M1) phenotype prone to foam cell differentiation, 10 or towards an antiinflammatory (M2) phenotype with scavenger activity. 11 The M1/M2 polarization balance of plaque macrophages and blood monocytes reflect pro-/anti-atherosclerotic conditions. Interestingly, IR primes M1 monocyte -macrophages, 12 while countering IR with peroxisome proliferator activating receptor-gamma activation can restore the M1/M2 balance. 13 In It can be speculated that CX 3 CR1 expression on monocytes interacts with VSMC-derived CX 3 CL1 to amplify the atherosclerotic process.
In biomedical research, the study of tissue-specific pathways if often replicated exploring patients' PBMC gene expression. 21 The translational nature of this mouse-to-human approach ( Figure 1 ) is important as it provides preliminary evidence that the identified pathway may be working
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also in humans. However, transferability of findings obtained in patients' PBMC to very different cellular models, such as human VSMC, may be problematic. Beyond the simple parallelism between cell types and the use of PBMC as surrogates/mirrors of pathological processes ongoing elsewhere, it is intriguing that monocytic CX 3 CR1 might be pathophysiologically involved in IR-induced atherosclerosis. Notwithstanding this general limitation, the novel data presented in the current issue of Cardiovascular Research provide intriguing evidence on the interplay between VSMCs and monocyte-macrophages in the accelerated atherosclerotic process induced by IR, through a common pathway driven by the CX 3 CL1/CX 3 CR1 axis. This mechanism should be pursued as a therapeutic target against IR-associated cardiovascular disease.
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